domenica, 3 maggio 2026

Notizie AIOM – anno XVII

FDA Approves Dasatinib for Pediatric Ph+ ALL

January 2, 2019 - The FDA has approved dasatinib tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval was based ...
Leggi tutto

EU Panel Backs Dasatinib for Pediatric Ph+ ALL

December 17, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome (Ph)-positive ...
Leggi tutto

Human medicines: highlights of 2018

January 4, 2019 - EMA has published an overview of its key recommendations of 2018 on the authorisation and safety monitoring of medicines for human use. New medicines are essential for public health as they can improve the treatment of diseases. In 2018, EMA recommended ...
Leggi tutto

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. A Systematic Review and Meta-analysis

Sex-associated differences in immune response are known, but a meta-analysis suggested men, compared with women, derive greater value from immunotherapy for advanced solid-organ malignant neoplasms. However, methodologic concerns and subsequent trials have placed these results ...
Leggi tutto

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non–small cell lung cancers (NSCLCs) undergo transformation to small-cell lung cancer (SCLC), but their clinical course is poorly characterized. We retrospectively identified patients with EGFR-mutant ...
Leggi tutto

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial

Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. We randomized 202 patients in a phase ...
Leggi tutto

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, firmate da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...
Leggi tutto

Dal Soroptimist International Club Genova a favore delle ragazze STEM

Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...
Leggi tutto

18 dicembre 2018 – Modifica posologia Registro Ceritinib (Novartis)

17 dicembre 2018 – Comunicazione EMA su acidi grassi omega-3